Please assess the completion status of the following clinical trial:

Trial Title: First in Man Study of the JenaValve TAVI Plus System Transfemoral

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with severe native aortic valve stenosis~* NYHA functional class II or higher~* Increased risk for surgical aortic valve replacement~* Comply with post-operative follow-up visits and requirements~Exclusion Criteria:~* Combined aortic valve disease with severe aortic insufficiency~* Presence of moderate mitral insufficiency or previous mitral prosthesis~* Severe pulmonary hypertension~* Congenital uni- or bicuspid aortic valve~* Endocarditis or active infection~* Life expectancy \< 12 months~* Need for emergency surgery for any reason

- Gender: ALL
- Minimum Age: 75 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Transcatheter Aortic Valve Replacement (Type: EXPERIMENTAL): In this study, transcatheter aortic valve replacement (TAVR) will be performed using the JenaValve Pericardial TAVR System, which is intended for use in subjects with severe aortic stenosis. The JenaValve replacement valve is placed inside the aortic valve by using a delivery system.

Based on this trial design, predict the completion outcome and termination type (if applicable).